We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evolving knowledge and therapy of inflammatory bowel disease.
- Authors
Korzenik, Joshua R.; Podolsky, Daniel K.
- Abstract
With recent advances in the understanding of its pathophysiology, inflammatory bowel disease has become a very active area for the development of novel therapeutic agents. New targets for biologics include cytokines involved in T-cell activation, with antibodies directed against IL-12 and interferon-γ. Selective adhesion molecule blockade has produced promising, though mixed, results. Recombinant human granulocyte–macrophage colony-stimulating factor might be effective in active Crohn's disease, presumably through stimulation of intestinal innate immune responses. With increasing evidence for a crucial role for luminal flora in maintaining the health of the bowel, strategies to manipulate intestinal bacteria using probiotics and prebiotics are being actively investigated as well.
- Subjects
INFLAMMATORY bowel diseases; ANTINEOPLASTIC agents; CROHN'S disease; ULCERATIVE colitis; INTERLEUKIN-12; CYTOKINES; INTERFERONS
- Publication
Nature Reviews Drug Discovery, 2006, Vol 5, Issue 3, p197
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd1986